MMSPORADGEN: The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma
Study Details
Study Description
Brief Summary
There is a growing body of data suggesting that the the risk of developing multiple myeloma, or myelomagenesis, is associated with genetic alterations occurring in the tumor cells. A limited number of candidate genes and polymorphisms have been reported in patients with this disease. In this study the investigators will compare the genetic information obtained on purified abnormal plasmocytes obtained from patients with multiple myeloma with available public databases in an effort to identify and if possible validate the role of certain mutations and/or polymorphisms in myelomagenesis. Plasmocytes will be obtained by immunomagnetic enrichment using CD138+ beads.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| patients with a diagnosis of multiple myeloma This study will involve a single patient group, namely patients with a diagnosis of multiple myeloma diagnosed by a bone marrow aspirate with cytological analysis of the bone marrow smear.Bone marrow samples obtained during the routine follow-up will undergo plasmocyte enrichment using immunopurification using CD138+ beads and nucleic acids will be extracted for sequencing. |
Genetic: DNA sequencing
The aim of this study is to perform DNA sequencing on abnormal plasmocytes obtained from patients with multiple myeloma, in order to identify alterations which are associated with the existence of this disease. DNA analyses will be performed in a single experiment once all samples have been collected.
|
Outcome Measures
Primary Outcome Measures
- DNA mutations associated with the existence of multiple myeloma [baseline, pre-intervention/procedure/surgery]
DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases.
- DNA mutations associated with the existence of multiple myeloma [during the intervention/procedure/surgery]
DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases.
- DNA mutations associated with the existence of multiple myeloma [immediately after the intervention/procedure/surgery]
DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases.
- DNA mutations associated with the existence of multiple myeloma [at 1 year]
DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases.
- DNA mutations associated with the existence of multiple myeloma [up to 24 weeks]
DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases.
- DNA mutations associated with the existence of multiple myeloma [through study completion, an average of 1 year]
DNA data acquired in myeloma patient samples will be compared to those of healthy subjects using publically available databases.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
diagnosis of multiple myeloma
-
availability of abnormal plasmocytes
Exclusion Criteria:
- none
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hospices Civils de Lyon | Pierre Benite | France | 69495 |
Sponsors and Collaborators
- Hospices Civils de Lyon
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 69HCL21_0492